Onconomics RGCC

Onconomics RGCC

Drug efficacy

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.

The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer.

Together, the results of these two testing methods provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer.

Test details

Sample Type

Blood or tissue for Central Nervous System Primary Tumors. Tissue sample.

Analysis period

Approx. 7 days

Cancer type

All types of Cancers

Final results

7–10 days

Sample size

15–25 ml peripheral whole blood. Qty: Minimum 400mg.


1750 €

* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.

Use our "intelligent filter" to find out which test is most suitable for your patients.